Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 291-299

  Aoe, Keisuke ^a   Kiura, Katsuyuki ^a   Ueoka, Hiroshi ^a   Tabata, Masahiro ^a   Matsumura, Tadashi ^a   Chikamori, Masakazu ^a   Matsushita, Akio ^a   Kohara, Hiroyuki ^a   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cisplatin; Docetaxel; Etoposide; Improved IC50 isobologram; Lung cancer; Median effect plot analysis; Vinorelbine

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0032922354     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P and Andre S: Preclinical evaluation of docetaxel (Taxotere). Sem Oncol 22: 3-16, 1995.
2. Ringel I and Horwitz SB: Studies with RP56976 (taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83: 288-291, 1991.
3. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
4. Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, van Meerbeek J, Wanders J, Franklin HR and Kaye S: Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group: Br J Cancer 70: 384-387, 1994.
5. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ and Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12: 1232-1237, 1994.
6. Fossella FV, Lee JS, Murphy WK, Lippman S Calayag M Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Hong WK and Raber M: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12: 1238-1244, 1994.
7. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK and Raber M: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645-651, 1995.
8. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H and Kaye SB: Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A: 1058-1060, 1994.
9. Chou TC and Talaly P: A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252: 6438-6442, 1977.
10. Chou TC and Talaly P: Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216, 1981.
11. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
12. Kishimoto N: Studies on cell biology and chemotherapy of lung cancer using tissue culture techniques Part 2. Biological characteristics of five newly established small cell lung cancer cell lines. Okayama Igakkai Zasshi 104: 905-913, 1992.
13. Watanabe Y: Experimental model of human lung cancer. Part I. Establishment and characterization of new tissue culture cell lines from human squamous cell carcinoma and adenocarcinoma of the lung. Okayama Igakkai Zasshi 97: 691-700, 1985.
14. Kiura K, Watarai S, Shibayama T, Ohnoshi T, Kimura I and Yasuda T: Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines. Anti-Cancer Drug Des 8: 417-428, 1993.
15. Yamane H, Kiura K, Tabata M, Bessho A, Tsuchida T, Motoda K, Hiraki A, Ueoka H and Harada M: Small cell lung cancer can express CD34 antigen. Anticancer Research 17: 3627-3632, 1997
16. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
17. Takigawa N, Ohnoshi T, Ueoka H, Kiura K, and Kimura I: Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46: 203-212, 1992.
18. Chang TT, Gulati S, Chou TC, Colvin M and Clarkson B: Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors. Cancer Res 47: 119-122, 1987.
19. Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized Quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994.
20. Knick VC, Eberwein DJ and Miller CG: Vinorelbine tartrate and paclitaxel combinations: Enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87: 1072-1077, 1995.
21. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
22. Gupta RS: Taxol resistant mutants of Chinese hamster ovary cells: genetic, biochemical, and cross-resistance studies. J Cell Physiol 114: 137-144, 1983.